Evidence map›Paper›PMID 35189909›Full record

ArticleSubstance abuse treatment, prevention, and policy2022

Daily cannabis use during the novel coronavirus disease (COVID-19) pandemic in Canada: a repeated cross-sectional study from May 2020 to December 2020.

Sameer Imtiaz, Samantha Wells, Jürgen Rehm, Christine M Wickens, Hayley Hamilton, Yeshambel T Nigatu, Damian Jankowicz, Tara Elton-Marshall

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Sameer ImtiazInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada. sameer.imtiaz@camh.ca.ORCID 0000-0001-6812-4892
Samantha WellsInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Jürgen RehmInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Christine M WickensInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Hayley HamiltonInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Yeshambel T NigatuInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Damian JankowiczInformation Management, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, ON, M6J 1H4, Canada.
Tara Elton-MarshallInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Centre for Addiction and Mental Health · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDaily cannabis use is most strongly implicated in the cannabis-attributable burden of disease. In the context of the novel coronavirus disease (COVID-19) pandemic in Canada, we characterized trends in daily cannabis use in the overall sample and various population subgroups, and examined risk characteristics associated with daily cannabis use.

methodsA cross-sectional design was operationalized using data from six waves of a national, online survey of adults residing in Canada who spoke English (N = 6,021; May-08 2020 to December-01 2020). Trends were characterized using the Cochran-Armitage test and risk characteristics were identified using chi-square test and logistic regression analysis.

resultsDaily cannabis use in the overall sample remained stable (5.34% - 6.10%; p = 0.30). This pattern of findings extended to various population subgroups as well. The odds of daily cannabis use were higher for those who: were males (Odds Ratio; 95% Confidence Interval: 1.46; 1.15 - 1.85), were between 18 - 29 years (2.36; 1.56 - 3.57), 30 - 39 years (2.65; 1.93 - 3.64) or 40-49 years (1.74; 1.19 - 2.54), self-identified as white (1.97; 1.47 - 2.64), had less than college or university completion (1.78; 1.39 - 2.28), engaged in heavy episodic drinking (2.05; 1.62 - 2.61), had a job that increased the risk of contracting COVID-19 (1.38; 1.01 - 1.88), experienced loneliness 5-7 days in the past week (1.86; 1.26 - 2.73) and felt very worried (2.08; 1.21 - 3.58) or somewhat worried (1.83; 1.11 - 3.01) about the pandemic's impact on their financial situation.

conclusionsDaily cannabis use did not change in the overall sample or various population subgroups during the pandemic. Pandemic-related risks and impacts were associated with daily cannabis use.

Indexed as

CannabisCOVID-19AdultCanadaCross-Sectional StudiesHumansPandemicsSARS-CoV-2CanadaCannabisCoronavirusCOVID-19MarijuanaSARS-CoV-2

Identifiers

PMID35189909
PMCPMC8860264
OpenAlexW4212899698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.